Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Net Income: 2010-2025

Historic Net Income for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $16.1 million.

  • Arrowhead Pharmaceuticals' Net Income rose 109.30% to $16.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.1 million, marking a year-over-year increase of 104.93%. This contributed to the annual value of $30.1 million for FY2025, which is 104.94% up from last year.
  • According to the latest figures from Q3 2025, Arrowhead Pharmaceuticals' Net Income is $16.1 million, which was up 109.02% from -$178.7 million recorded in Q2 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Net Income peaked at $367.8 million during Q1 2025, and registered a low of -$178.7 million during Q2 2025.
  • Its 3-year average for Net Income is -$67.9 million, with a median of -$127.0 million in 2024.
  • Its Net Income has fluctuated over the past 5 years, first slumped by 366.37% in 2024, then soared by 389.63% in 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Net Income (Quarterly) stood at -$62.9 million in 2021, then surged by 33.50% to -$41.8 million in 2022, then tumbled by 223.78% to -$135.4 million in 2023, then decreased by 29.43% to -$175.2 million in 2024, then skyrocketed by 109.30% to $16.1 million in 2025.
  • Its last three reported values are $16.1 million in Q3 2025, -$178.7 million for Q2 2025, and $367.8 million during Q1 2025.